Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 4/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5305665 | 0.86 | HDAC1 (0.35) | HDAC1HDAC6DGAT1KDM1AKDM1B | |
| SCHEMBL28872076 | 0.86 | CYP3A4 (0.38) | HDAC1HDAC6DGAT1ALDH1A1KDM1A | |
| SCHEMBL26234359 | 0.84 | NMT1 (0.37) | HDAC1HDAC6ALDH1A1MAPK1TDP1 | |
| SCHEMBL25188992 | 0.82 | HDAC1 (0.33) | HDAC1HDAC6ALDH1A1 | |
| SCHEMBL3696910 | 0.82 | HDAC1 (0.33) | HDAC1HDAC6 | |
| SCHEMBL560909 | 0.82 | CYP3A4 (0.35) | HDAC1HDAC6DGAT1ALDH1A1MAPK1 | |
| SCHEMBL21593326 | 0.78 | NQO2 (0.41) | ALDH1A1MAPT | |
| SCHEMBL24012991 | 0.77 | HDAC1 (0.34) | HDAC1HDAC6ALDH1A1MAPK1MAPT | |
| SCHEMBL24012721 | 0.77 | ERN1 (0.44) | HDAC1HDAC6ALDH1A1TSHR | |
| SCHEMBL21415482 | 0.77 | HDAC1 (0.31) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692101-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | Alfa Instruments S.r.l. (IT) | 2020-08-12 | — | — | EP | claimed |
| WO-2019068935-A1 | BRILLIANT BLUE (BBG) DYE DERIVATIVES AND STAINING COMPOSITIONS COMPRISING THE SAME FOR SELECTIVELY STAINING BIOLOGICAL SUBSTRATES | ALFA INSTRUMENTS S.R.L. (IT) | 2019-04-11 | — | — | WO | claimed |
| CN-103951688-B | One prepares the method for the fluoro-4-methylphenylboronic acid of 3,5-bis- | ASLEE BIOPHARMACEUTICALS, INC. (CN) | 2016-04-20 | — | — | CN | claimed |
| CN-103951688-A | Method for preparing 3,5-difluoro-4-methyl phenylboronic acid | ASLEE BIOPHARMACEUTICALS INC | 2014-07-30 | — | — | CN | claimed |
| US-12552824-B2 | C-mannoside compounds useful for the treatment of urinary tract infections | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20260015367-A1 | BORON-CONTAINING COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT USING SAME | KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORP (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4658656-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | BEONE MEDICINES I GMBH (CH) | 2025-11-13 | — | — | US | disclosed |
| WO-2025224262-A1 | COMBINATION THERAPIES COMPRISING A CDK2 DEGRADER AND A CDK4/6 INHIBITOR | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025224249-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS AG (CH) | 2025-10-30 | — | — | WO | disclosed |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| US-6034119-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| EP-0963371-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5968935-A | ADMINISTERING TO TREAT NERVOUS SYSTEM DISORDERS | TOYAMA CHEMICAL CO.., LTD. (JP) | 1999-10-19 | — | — | US | disclosed |
| US-5932620-A | Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-08-03 | — | — | US | disclosed |
| US-5922721-A | USE IN TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S CHOREA, AMYOTROPHIC LATERAL SCLEROSIS AND TRAUAMTIC NERVE INJURIES | TOYAMA CHEMICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5807887-A | COGNITION ACTIVATOR; ALZHEIMER*S, HUNTINGTON DISEASE | TOYAMA CHEMICAL CO., LTD. (JP) | 1998-09-15 | — | — | US | disclosed |
| WO-1998037072-A1 | SUBSTITUTED BENZIMIDAZOLES AS NON-NUCLEOSIDE INHIBITORS OF REVERSE TRANSCRIPTASE | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-08-27 | — | — | WO | disclosed |
| EP-0790246-A1 | POTENTIATOR FOR NERVE GROWTH FACTOR ACTIVITY CONTAINING 1,2-ETHANEDIOL DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | HDAC1 989/4885HDAC6 500/4885DGAT1 2299/4885 |
| US-20250346597-A1 | CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES | DGKG, DGKA, DGKK | HDAC1 609/4885HDAC6 966/4885DGAT1 21/4885 |
| US-20250326766-A1 | RIPK1 INHIBITORS AND METHODS OF USE | RIPK1, RIPK2, RIPK3 | HDAC1 481/4885HDAC6 733/4885DGAT1 1367/4885 |
| US-12552824-B2 | C-mannoside compounds useful for the treatment of urinary tract infections | MUC1, CD209, MAN2B2 | HDAC1 1165/4885HDAC6 283/4885DGAT1 4552/4885 |
| US-20260015367-A1 | BORON-CONTAINING COMPOUND, LIGHT-EMITTING MATERIAL AND LIGHT-EMITTING ELEMENT USING SAME | EBPL, TBL3, TBL2 | HDAC1 2621/4885HDAC6 4500/4885DGAT1 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.